top of page

Pediatric DTG Implementation Memo (English, French)

  • hivtoolkit
  • Oct 11, 2021
  • 1 min read

Updated: Jan 13, 2022



CHAI has developed this memo to lay out information for national HIV programs considering the introduction of pediatric dolutegravir 10 mg dispersible, scored tablets, a newly available generic formulation of DTG that the World Health Organization recommends as the preferred first-line antiretroviral therapy for children living with HIV who are at least 4 weeks of age and weigh at least 3 and up to 20kg.


Comments


  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • YouTube

383 Dorchester Avenue, Suite 400

Boston, MA 02127

The goal of the HIV New Product Introduction Toolkit is to stimulate conversations between government, partners, and communities on new product introduction. Please feel free to share any thoughts, questions, or additional resources for consideration by contacting us via email at HIVToolkit@clintonhealthaccess.org.

 

© 2022  Clinton Health Access Initiative - Global HIV Access Program

bottom of page